Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review

Hereditary Cancer in Clinical Practice

Volumn 11, Issue 1, 2013, Pages

  Tutlewska, Katarzyna ^a   Lubinski, Jan ^a   Kurzawski, Grzegorz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Colon cancer; EPCAM gene; Lynch syndrome; MSH2 hypermethylation

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; PROTEIN MSH2;

CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; ENDOMETRIUM CANCER; EPIGENETICS; EXON; GENE DELETION; GENE INACTIVATION; GENE SILENCING; GENETIC ASSOCIATION; GERM LINE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRACTICE GUIDELINE; PREVALENCE; PROMOTER REGION; REVIEW;

EID: 84881134721     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-11-9     Document Type: Review

References (34)

1. Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubiński J, Müller H, Ponz De Leon M, Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 2010, 9:109-115. 10.1007/s10689-009-9291-3, 19763885.
2. Ligtenberg MJL, Kuiper RP, van Kessel AG, Hoogerbrugge N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 2012, 10.1007/s10689-012-9591-x.
3. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz De Leon M, Rustgi AK, Castells A. EPICOLON consortium: identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012, 308:1555-65. 10.1001/jama.2012.13088, 23073952.
4. Musulen E, Blanco I, Carrato C, Fernandez-Figueras MT, Pineda M, Capella G, Ariza A. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. Hum Pathol 2013, 44:412-6. 10.1016/j.humpath.2012.06.006, 23026194.
5. Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Ligtenberg MJ. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011, 32:407-14. 10.1002/humu.21446, 21309036.
6. Hemminki A, Peltomäki P, Mecklin JP, Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A, Aaltonen LA. Loss of the wild type MLH-1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nature 1994, 8:405-10.
7. Huth C, Kloor M, Voigt A, Bozukova G, Evers C, Gaspar H, Tariverdian M, Schirmacher P, Doeberitz M, Bläker H. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 2012, 25:911-6. 10.1038/modpathol.2012.30, 22388758.
8. Peltomäki P, Lothe RA, Aaltonen LA, Pylkkänen L, Nyström-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A. Microsatellite instability is associated with tumors that characterized the hereditary non-polyposis carcinoma syndrome. Cancer Res 1993, 53:5853-5.
9. Guarinos C, Castillejo A, Barberá VM, Pérez-Carbonell L, Sánchez-Heras AB, Segura A, Guillén-Ponce C, Martínez-Cantó A, Castillejo MI, Egoavil CM, Jover R, Payá A, Alenda C, Soto JL. EPCAM Germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn 2010, 12:765-70. 10.2353/jmoldx.2010.100039, 2963912, 20864635.
10. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz De Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Möslein G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62:812-23. 10.1136/gutjnl-2012-304356, 3647358, 23408351.
11. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-8. 10.1093/jnci/djh034, 2933058, 14970275.
12. Kładny J, Lubiński J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract 2008, 6:99-102. 10.1186/1897-4287-6-2-99, 2735811, 19804605.
13. Nagasaka T, Rhees J, Kloor M, Gebert J, Naomoto Y, Boland CR, Goel A. Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 2010, 70:3098-108. 10.1158/0008-5472.CAN-09-3290, 2856102, 20388775.
14. Suter CM, Martin DI. Inherited epimutation or a haplotypic basis for propensity to silence?. Nat Genet 2007, 39:573.
15. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Eng J Med 2007, 356:697-705.
16. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006, 38:1178-83. 10.1038/ng1866, 16951683.
17. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002, 62:3925-8.
18. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009, 30:197-203. 10.1002/humu.20942, 19177550.
19. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009, 41:112-7. 10.1038/ng.283, 19098912.
20. Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, Ligtenberg MJ. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011, 12:49-55. 10.1016/S1470-2045(10)70265-5, 3670774, 21145788.
21. Pérez-Cabornero L, Infante Sanz M, Velasco Sampedro E, Lastra Aras E, Acedo Becares A, Miner Pino C, Durán Domínguez M. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5/ part of MSH2. Cancer Prev Res 2011, 4:1556-62.
22. Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes cancer 2009, 48:737-744. 10.1002/gcc.20678, 19455606.
23. Munz M, Baeuerle PA, Gires O. The emerging role of EPCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-9. 10.1158/0008-5472.CAN-09-0654, 19584271.
24. Sivagnanam M, Schaible T, Szigeti R, Byrd RH, Finegold MJ, Ranganathan S, Gopalakrishna GS, Tatevian N, Kellermayer R. Further evidence for EPCAM as the gene for congenital tufting enteropathy. Am J Med Genet 2010, 152A:222-4. 10.1002/ajmg.a.33186, 20034091.
25. van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes W, Lynch H, Burn J, Möslein G, Fodde R. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6 and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005, 44:123-138. 10.1002/gcc.20219, 15942939.
26. Jurka J. Evolutionary impact of human Alu repetitive elements. Curr Opin Genet 2004, 14:603-8.
27. Hitchins MP, Burn J. Alu in Lynch syndrome: a danger SINE?. Cancer Prev Res 2011, 4:1527-30.
28. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet 2009, 76:1-18.
29. Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S. Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. Clin Genet 2012, 82:97-9. 10.1111/j.1399-0004.2011.01826.x, 22243433.
30. Lynch HT, Riegert-Johnson DL, Snyder C, Lynch JF, Hagenkord J, Boland CR, Rhees J, Thibodeau SN, Boardman LA, Davies J, Kuiper RP, Hoogerbrugge N, Ligtenberg MJ. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 2011, 106:1829-1836. 10.1038/ajg.2011.203, 21769135.
31. Pineda M, González S, Lázaro C, Blanco I, Capellá G. Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 2010, 693:19-31. 10.1016/j.mrfmmm.2009.11.002, 19931546.
32. Caldés T, Blanco I, Soto J, Capellá G, Lázaro C, Cajal T, Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón Y. Identyfication of a founder EPCAM deletion in Spanish Lynch syndrome families. Clin Genet 2013, 2013:2013. 10.1111/cge.12152.
33. Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel DM, Bläker H. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 2011, 29:223-7. 10.1200/JCO.2010.32.0820, 21115857.
34. Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T. ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 10.1016/j.jmoldx.2012.03.002, 3391416, 22658618.